CanSino Biologics Inc.
6185.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.43B
Close$
Share Statistics
| Market cap | $7.43 Billion |
|---|---|
| Enterprise Value | $7.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.11 |
| Beta | 1.13 |
| Outstanding Shares | 247,043,801 |
Return
| Return on Equity | 0.82% |
|---|---|
| Return on Assets | 0.59% |
| Return on Invested Capital | -0.40% |
Valuation & Multiples
| P/E Ratio | 502.09 |
|---|---|
| PEG | -23.48 |
| Price to Sales | 7.52 |
| Price to Book Ratio | 1.5 |
| Enterprise Value to Revenue | 5.92 |
| Enterprise Value to EBIT | -294.64 |
| Enterprise Value to Net Income | 178 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
$0.24
Average shareholder expectationRevenue Estimate
$360.88 M
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$0.29
Average shareholder expectationRevenue Estimate
$466.73 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About CanSino Biologics Inc.
1,175 employees
CEO: Xue Feng Yu CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an...